Chelation therapy for the management of diabetic complications: a hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma

References

1. Goh SY, Cooper ME. The role of advanced glycation end-products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143–52.10.1210/jc.2007-1817Search in Google Scholar

2. Negre-Salvayre A, Salvayre R, Auge N, Pamplona R, Portero-Otin M. Hyperglycemia and glycation in diabetic complications. Antiox Redox Signal 2009;11:3071–109.10.1089/ars.2009.2484Search in Google Scholar

3. Pamplona R, Naudí A, Gavín R, Pastrana MA, Sajnani G, Ilieva EV, et al. Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radic Biol Med 2008;45:1159–66.10.1016/j.freeradbiomed.2008.07.009Search in Google Scholar

4. Pamplona R, Portero-Otín M, Requena J, Gredilla R, Barja G. Oxidative, glycoxidative and lipoxidative damage to rat heart mitochondrial proteins is lower after 4 months of caloric restriction than in age-matched controls. Mech Ageing Dev 2002;123:1437–46.10.1016/S0047-6374(02)00076-3Search in Google Scholar

5. Ramaswamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol 2012;57:160–7.10.1016/j.vph.2012.06.004Search in Google Scholar PubMed PubMed Central

6. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003;25: 283–92.10.1007/s00726-003-0029-5Search in Google Scholar PubMed

7. Hodgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway: implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:2275–81.10.1161/ATVBAHA.108.175992Search in Google Scholar PubMed

8. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000;275:21177–84.10.1074/jbc.M003263200Search in Google Scholar PubMed

9. Chetrykin SV, Mathis ME, Ham AJ, Hachey DL, Hudson BG, Voziyan PA. Propagation of protein glycation damage involves modification of tryptophan residues by reactive oxygen species: inhibition by pyridoxamine. Free Radic Biol Med 2008; 44:1276–85.10.1016/j.freeradbiomed.2007.09.016Search in Google Scholar PubMed

10. Chetrykin S, Mathis M, Hayes McDonald W, Shackelford X, Hudson BG, Voziyan PA. Pyridoxamine protects protein backbone from oxidative fragmentation. Biochem Biophys Res Commun 2011;411:574–9.10.1016/j.bbrc.2011.06.188Search in Google Scholar PubMed PubMed Central

11. Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012;61:549–59.10.2337/db11-1120Search in Google Scholar PubMed PubMed Central

12. Rahbar S, Figarola JL. Inhibitors and breakers of advanced glycation endproducts (AGEs): a review. Curr Med Chem Immunol Endocr Metab Agents 2002;2:135–61.10.2174/1568013023358889Search in Google Scholar

13. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003;419:63–9.10.1016/j.abb.2003.08.009Search in Google Scholar PubMed

14. Cooper GJ. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer’s disease. Drugs 2011;71:1281–320.10.2165/11591370-000000000-00000Search in Google Scholar PubMed

15. Cooper GJ. Selective divalent copper chelation for the treatment of diabetes mellitus. Curr Med Chem 2012;19:2828–60.10.2174/092986712800609715Search in Google Scholar PubMed

16. Stiles S. TACT: surprising, puzzling benefit from chelation therapy after MI. Available from: www.theheart.org. Accessed 4 November, 2012.Search in Google Scholar

17. Logie L, Harthill J, Patel K, Bacon S, Hamilton DL, Macrae K, et al. Cellular responses to the metal-binding properties of metformin. Diabetes 2012;61:1423–33.10.2337/db11-0961Search in Google Scholar PubMed PubMed Central

18. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629–32.10.1126/science.3487117Search in Google Scholar PubMed

19. Vasan S, Zhang X, Zhang X, Kapurniotu A, Berhnagen J, Teichberg S, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275–8.10.1038/382275a0Search in Google Scholar PubMed

20. Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy. Endocrinology 2007;148:886–95.10.1210/en.2006-1300Search in Google Scholar PubMed

21. Sourris KC, Harcourt BE, Forbes JM. A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches. Am J Nephrol 2009;30:323–35.10.1159/000226586Search in Google Scholar PubMed

22. Baynes JW, Murray DB. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp Diab Res 2009;2009:696378.Search in Google Scholar

23. Nagai R, Nagai M, Shimasaki S, Baynes JW, Fujiwara Y. Citric acid inhibits development of cataracts and ketosis in streptozotocin (type 1) diabetic rats. Biochem Biophys Res Commun 2010;393:118–22.10.1016/j.bbrc.2010.01.095Search in Google Scholar PubMed PubMed Central

24. Wei H, Zhang WJ, McMillen TS, LeBoeuf RC, Frei B. Copper chelation by tetrathiomolybdate inhibits vascular inflammation and atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis 2012:223:306–13.10.1016/j.atherosclerosis.2012.06.013Search in Google Scholar PubMed PubMed Central

25. Sundararaman S, Vonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 2007;30:1926–33.10.2337/dc06-2625Search in Google Scholar PubMed

26. Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB. The role of iron in type 2 diabetes in humans. Biochim Biophys Acta 2009;1790:671–81.10.1016/j.bbagen.2008.04.005Search in Google Scholar PubMed

27. Stanley N, Stadler N, Woods AA, Bannon PG, Davies MJ. Concentrations of iron correlate with the extent of protein, but not lipid, oxidation in advanced human atherosclerotic lesions. Free Radic Biol Med 2006;40:1636–43.10.1016/j.freeradbiomed.2005.12.031Search in Google Scholar PubMed

28. Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta 2009;1790:718–23.10.1016/j.bbagen.2008.06.005Search in Google Scholar PubMed

29. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866–8.10.1073/pnas.94.18.9866Search in Google Scholar PubMed PubMed Central

30. Castellani RJ, Moreira PI, Perry G, Zhu X. The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors 2012;38:133–8.10.1002/biof.1010Search in Google Scholar PubMed

31. Minqin R, Rajendran R, Pan N, Tan BK, Ong WY, Watt F, et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med 2005;32:1206–11.10.1016/j.freeradbiomed.2005.01.008Search in Google Scholar PubMed

32. Zhang WJ, Wei H, Frei B. The iron chelator, desferoxamine, reduces inflammation and atherosclerotic lesions in experimental mice. Exp Biol Med 2010;235:633–41.10.1258/ebm.2009.009229Search in Google Scholar PubMed PubMed Central

33. Hider RC, Roy S, Ma YM, Le-Kong X, Preston J. The potential application of iron chelators for the treatment of neurodegenerative diseases. Metallomics 2011;3:239–49.10.1039/c0mt00087fSearch in Google Scholar

34. Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm 2011;118:473–7.10.1007/s00702-010-0518-0Search in Google Scholar

35. Budimir A. Metal ions, Alzheimer’s disease and chelation therapy. Acta Pharm 2011;61:1–14.10.2478/v10007-011-0006-6Search in Google Scholar

36. Ayton S, Lei P, Bush AI. Metallostasis in Alzheimer disease. Free Radic Biol Med 2012 Nov 9. doi:pii: S0891-5849(12)01800-X [Epub ahead of print].Search in Google Scholar

37. Brewer GJ. Copper toxicity in Alzheimer’s disease: cognitive loss from ingestion of inorganic copper. J Trace Elem Med Biol 2012;26:89–92.10.1016/j.jtemb.2012.04.019Search in Google Scholar

38. Brewer GJ. Metals in the causation and treatment of Wilson’s disease and Alzheimer’s disease, and copper lowering therapy in medicine. Inorg Chim Acta 2012;393:135–41.10.1016/j.ica.2012.06.014Search in Google Scholar

39. Sparks DL, Schreurs BG. Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer’s disease. Proc Natl Acad Sci USA 2003;100:11065–9.10.1073/pnas.1832769100Search in Google Scholar

40. Sparks DL, Friedland R, Petanceska S, Schreurs BG, Shi J, Perry G, et al. Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging 2006;10:247–54.Search in Google Scholar

41. Morris MC, Evans DA, Tangney CC, Bienias JL, Schneider JA, Wilson RS, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 2006;63:1085–8.10.1001/archneur.63.8.1085Search in Google Scholar

42. Loef M, Walach H. Copper and iron in Alzheimer’s disease: a systematic review and its dietary implications. Br J Nutr 2012;107:7–19.10.1017/S000711451100376XSearch in Google Scholar

43. Eskici G, Axelsen PH. Copper and oxidative stress in the pathogenesis of Alzheimer’s disease. Biochemistry 2012;51:6289–311.10.1021/bi3006169Search in Google Scholar

44. Buettner GR. Use of ascorbate as a test of catalytic metals in simple buffers. Methods Enzymol 1990;186:125–7.10.1016/0076-6879(90)86100-ASearch in Google Scholar

45. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991;10:339–52.10.1016/0891-5849(91)90040-ASearch in Google Scholar

46. Udenfriend S, Clark CT, Axelrod J, Brodie BB. Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. J Biol Chem 1954;208:731–39.10.1016/S0021-9258(18)65598-XSearch in Google Scholar

47. Brodie BM, Axelrod J, Shore PA, Udenfriend S. Ascorbic acid in aromatic hydroxylation. II. Products formed by reaction of substrates with ascorbic acid, ferrous iron and oxygen. J Biol Chem 1954;208:741–50.10.1016/S0021-9258(18)65599-1Search in Google Scholar

48. Amici A, Levine RL, Tsai L, Stadtman ER. Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivatives by metal-catalyzed oxidation reactions. J Biol Chem 1989;264:3341–6.10.1016/S0021-9258(18)94071-8Search in Google Scholar

49. Refsgaard HH, Tsai L, Stadtman ER. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA 2000;97:611–6.10.1073/pnas.97.2.611Search in Google Scholar PubMed PubMed Central

50. Stumm W, Lee GF. Oxygenation of ferrous ion. Ind Eng Chem 1961;53:143–6.10.1021/ie50614a030Search in Google Scholar

51. Howells C, Saar K, Eaton E, Ray S, Palumaa P, Shabala L, et al. Redox-active Cu(II)-Aβ causes substantial changes in axonal integrity in cultured cortical neurons in an oxidative-stress dependent manner. Exp Neurol 2012;237:499–506.10.1016/j.expneurol.2012.06.002Search in Google Scholar PubMed

52. Qian M, Liu M, Eaton JW. Transitions metals bind to glycated proteins forming redox active “glycochelates”: implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 1998;250:385–9.10.1006/bbrc.1998.9326Search in Google Scholar PubMed

53. Saxena P, Saxena AK, Cui XL, Obrenovich M, Gudipaty K, Monnier VM. Transition metal-catalyzed oxidation of ascorbate in human cataract extracts. Possible role of advanced glycation end products. Invest Ophthalmol Vis Sci 2000;41:1473–81.Search in Google Scholar

54. Feaga HA, Maduka RC, Foster MN, Szalai VA. Affinity of Cu+ for the copper binding domain of the β-amyloid peptide of Alzheimer’s disease. Inorg Chem 2011;50:1614–8.10.1021/ic100967sSearch in Google Scholar PubMed

55. Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. J Agric Food Chem 2005;53:1841–56.10.1021/jf030723cSearch in Google Scholar PubMed

56. Apak R, Guclu K, Demirata B, Ozyurek M, Celik SE, Bektasoglu B, et al. Comparative evaluation of various total antioxidant capacity assays applied to phenolic compounds with the CUPRAC assay. Molecules 2007;12:1496–547.10.3390/12071496Search in Google Scholar PubMed PubMed Central

57. McMillin GA, Travis JJ, Hunt JW. Direct measurement of free copper in serum or plasma ultrafiltrate. Clin Chem 2009:131:160–5.10.1309/AJCP7Z9KBFINVGYFSearch in Google Scholar PubMed

58. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349–56.10.1681/ASN.V9122349Search in Google Scholar PubMed

59. Miyata T, Wada T, Cai Z, Iida Y, Horie K, Yasuda Y, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal disease. Kidney Int 1997;51:1170–81.10.1038/ki.1997.160Search in Google Scholar PubMed

60. Lee KW, Mossine V, Ortwerth BJ. The relative ability of glucose and ascorbate to glycated and crosslink lens proteins in vitro. Exp Eye Res 1998;67:95–104.10.1006/exer.1998.0500Search in Google Scholar PubMed